Cargando…

Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand

BACKGROUND: Small intestinal Neuroendocrine Neoplasms (SI‐NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI‐NEN in Auckland, Aotearoa New Zealand (AoNZ). METHODS: A retrospective study of all patients diagnosed wit...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuinness, Matthew J., Woodhouse, Braden, Harmston, Christopher, Parker, Kate, Kramer, Nicole, Findlay, Michael, Print, Cristin, Merrie, Arend, Lawrence, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541869/
https://www.ncbi.nlm.nih.gov/pubmed/35762209
http://dx.doi.org/10.1111/ans.17851
_version_ 1784804021132853248
author McGuinness, Matthew J.
Woodhouse, Braden
Harmston, Christopher
Parker, Kate
Kramer, Nicole
Findlay, Michael
Print, Cristin
Merrie, Arend
Lawrence, Ben
author_facet McGuinness, Matthew J.
Woodhouse, Braden
Harmston, Christopher
Parker, Kate
Kramer, Nicole
Findlay, Michael
Print, Cristin
Merrie, Arend
Lawrence, Ben
author_sort McGuinness, Matthew J.
collection PubMed
description BACKGROUND: Small intestinal Neuroendocrine Neoplasms (SI‐NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI‐NEN in Auckland, Aotearoa New Zealand (AoNZ). METHODS: A retrospective study of all patients diagnosed with a jejunal or ileal SI‐NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data. RESULTS: One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10‐year disease‐specific survival for all patients was 66.1% (95% CI 56.5–75.7%) and 61.8% (95% CI 51.8–71.8%), respectively. Ten‐year disease‐specific survival was 100% for stage I and II, 74% (95%CI 61.7–84.4%) for stage III and 33.9% (95%CI 16.9–35.6%) for stage IV SI‐NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92–5.5) nor distant resection (HR 1.72, 95% CI 0.63–4.7) were significantly associated with a disease‐specific or overall survival benefit. CONCLUSION: This study demonstrates that stage at SI‐NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection.
format Online
Article
Text
id pubmed-9541869
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-95418692022-10-14 Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand McGuinness, Matthew J. Woodhouse, Braden Harmston, Christopher Parker, Kate Kramer, Nicole Findlay, Michael Print, Cristin Merrie, Arend Lawrence, Ben ANZ J Surg General Surgery BACKGROUND: Small intestinal Neuroendocrine Neoplasms (SI‐NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI‐NEN in Auckland, Aotearoa New Zealand (AoNZ). METHODS: A retrospective study of all patients diagnosed with a jejunal or ileal SI‐NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data. RESULTS: One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10‐year disease‐specific survival for all patients was 66.1% (95% CI 56.5–75.7%) and 61.8% (95% CI 51.8–71.8%), respectively. Ten‐year disease‐specific survival was 100% for stage I and II, 74% (95%CI 61.7–84.4%) for stage III and 33.9% (95%CI 16.9–35.6%) for stage IV SI‐NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92–5.5) nor distant resection (HR 1.72, 95% CI 0.63–4.7) were significantly associated with a disease‐specific or overall survival benefit. CONCLUSION: This study demonstrates that stage at SI‐NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection. John Wiley & Sons Australia, Ltd 2022-06-28 2022 /pmc/articles/PMC9541869/ /pubmed/35762209 http://dx.doi.org/10.1111/ans.17851 Text en © 2022 The Authors. ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle General Surgery
McGuinness, Matthew J.
Woodhouse, Braden
Harmston, Christopher
Parker, Kate
Kramer, Nicole
Findlay, Michael
Print, Cristin
Merrie, Arend
Lawrence, Ben
Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand
title Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand
title_full Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand
title_fullStr Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand
title_full_unstemmed Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand
title_short Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand
title_sort survival of patients with small bowel neuroendocrine neoplasms in auckland, aotearoa new zealand
topic General Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541869/
https://www.ncbi.nlm.nih.gov/pubmed/35762209
http://dx.doi.org/10.1111/ans.17851
work_keys_str_mv AT mcguinnessmatthewj survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand
AT woodhousebraden survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand
AT harmstonchristopher survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand
AT parkerkate survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand
AT kramernicole survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand
AT findlaymichael survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand
AT printcristin survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand
AT merriearend survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand
AT lawrenceben survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand